AimwellBio's live signal intelligence engine is now tracking 13 source streams in real time - FDA actions, drug recalls, clinical trials, patent filings, global outbreaks, and regulatory divergence. It's running right now. The only question is whether you're seeing what it sees.
Read More
New CFO brings public-company reporting, manufacturing finance, technical accounting, governance, and cash-flow planning experience in-house as Worksport scales toward its 2026 growth targets.
Read MoreProgram Enters Final Stage of Dose Optimization
Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset
Read MoreThe IRS is running its AI-powered audit selection system six times annually - and freelancers, independent contractors, and gig workers are squarely in the crosshairs.
Read More
Double board-certified facial plastic surgeon now offers Renuva at Laser & Cosmetic Surgery Specialists in Newburgh, NY and Rubinstein Plastic Surgery Center in Montvale, NJ
Read MoreTransaction Provides Exposure for Alset AI to Important Critical Minerals in the Global Energy Transition while Improving Lyken.AI's Financial Position as it Pursues Strategic Growth Opportunities
Read More
ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible for up to $580 million in future milestone payments
Rusfertide NDA accepted and granted Priority Review by FDA, with a Prescription Drug User Fee Act target action date in the third quarter of 2026
Protagonist exercised its rusfertide opt-out right under the Takeda collaboration on April 28, triggering a $200 million opt-out fee payable to the Company; eligible for additional $200 million opt-out and $75 million milestone payments upon NDA approval, sales milestones of up to $775 million and worldwide royalties ranging from 14% to 29%
PN-881 (oral IL-17 antagonist peptide) Phase 1 study completion by mid-2026 and Phase 2 initiation anticipated by year-end; PN-477sc and PN-477o (sc and oral triple GLP/GIP/GICG agonist) Phase 1 initiation expected in mid-2026 and Q1 2027, respectively
Cash, cash equivalents and marketable securities of $620 million as of March 31, 2026, anticipated to provide cash runway through at least 2028
Read More
Block transfer model ensures associate degree graduates enter Unity at junior-year standing, no lost credits, no lost time
Article updated May 13, 2026 to remove incorrect last name of "Coffers"
Read More
Green River Lithium Project JORC Resource estimate increased by 650%
Indicated Resource - 183,000 t of lithium carbonate (863% increase),
Inferred Resource - 590,000 t of lithium carbonate (602% increase),
The interpreted Mineral Resource estimate based on the Mississippian Unit only
Potential to further increase as the Unit has not been completely drilled thorough,
Upgrade is due to new drilling data and additional area resulting in higher confidence level in the stratigraphic thickness and lithium concentration,
Scope to increase Indicated and Inferred Mineral Resource, with granting of additional claims.
Vadzo Imaging's Innova GigE camera series addresses multi-node frame synchronization, high-contrast scene handling, and sub-microsecond PTP alignment demands of warehouse automation and logistics infrastructure across five sensor-specific configurations - Sony STARVIS, Sony STARVIS 2, Sony Pregius S, and Onsemi AR0234 delivering ONVIF-compliant, PoE-powered Warehouse Automation GigE Camera deployments purpose-built for AMR coordination, conveyor inspection, dock monitoring, and facility-wide machine vision networks.
Read MoreBuilt on more than 22 years of trusted primary source verification, Propelus Data Solutions delivers the deepest coverage, the most accurate data, and the only platform purpose-built for healthcare's real compliance demands
Read More
